2-[[2-(4-羟基苯基)乙胺基]甲基]-3,4-二氢-2H-萘-1-酮 | 40077-13-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 2-[[2-(4-羟基苯基)乙胺基]甲基]-3,4-二氢-2H-萘-1-酮
• 英文名称: 2-[β-(4-hydroxyphenyl)-ethyl-aminomethyl]tetralone
• 英文别名: BE 2254；2-[β-(4-hydroxyphenyl)ethylaminomethyl]tetralone；BE2254；HEAT；2-({[2-(4-Hydroxyphenyl)ethyl]amino}methyl)-2,3,4-trihydronaphthalen-1-one；2-{[β-(4-Hydroxyphenyl) ethyl]aminomethyl}-1-tetralone；2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
• CAS: 40077-13-2
• 化学式: C₁₉H₂₁NO₂
• 分子量: 295.381
• InChiKey: PZZOEXPDTYIBPI-UHFFFAOYSA-N

物化性质

• 沸点：
  492.8±25.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 2-[[2-(4-羟基苯基)乙胺基]甲基]-3,4-二氢-2H-萘-1-酮 以 二氯甲烷 为溶剂， 以2.32 g (51%)的产率得到2-((β-(4-Hydroxyphenyl)ethyl)t-butoxycarbonylaminomethyl)-1-tetralone
  参考文献：
  名称：

  Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist

  摘要：

  揭示了硝化和亚硝化α-肾上腺素受体拮抗剂，包括一种α-肾上腺素受体拮抗剂（α-拮抗剂）的组合物，该组合物可以选择性地被至少一个NO或NO.sub.2基团取代，以及一种作为带电物种（即亚硝酸盐（NO.sup.+）或亚硝基（NO.sup.-））或中性物种（亚硝酸（NO.cndot.））提供、转移或释放一氧化氮的化合物；以及它们在治疗人类阳痿或勃起功能障碍中的用途。

  公开号：

  US05994294A1
• 作为产物：
  描述：

  聚合甲醛 、 酪胺盐酸盐 、 3,4-二氢-1(2H)-萘酮 以 异丙醇 为溶剂， 生成 2-[[2-(4-羟基苯基)乙胺基]甲基]-3,4-二氢-2H-萘-1-酮
  参考文献：
  名称：

  DE1913199

  摘要：

  公开号：

文献信息

• Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
  申请人：——

  公开号：US20020143007A1

  公开（公告）日：2002-10-03

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型硝化和/或硝基化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或硝基化α-肾上腺素受体拮抗剂的新型组合物，以及可选地包含一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物的化合物，和/或一种或多种血管活性药物。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物，和/或一种或多种血管活性药物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应，以及治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，以及逆转麻醉状态的方法。
• Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds
  申请人：Garvey S. David

  公开号：US20050187222A1

  公开（公告）日：2005-08-25

  The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型的硝化和/或亚硝化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或亚硝化α-肾上腺素受体拮抗剂的新型组合物，以及可选地，一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物和/或一种或多种血管活性剂。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的新型组合物。本发明还提供了用于治疗或预防男女性功能障碍、增强男女性反应、治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、切欲性尿失禁或膀胱过度活动，并逆转麻醉状态的方法。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS
  申请人：caprotec bioanalytics GmbH

  公开号：EP1485707B1

  公开（公告）日：2009-01-14
• TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS
  申请人：Psychogenics Inc.

  公开号：EP2858649B1

  公开（公告）日：2019-10-23